Tokyo (SCCIJ) – ABB Robotics and the U.S. biotech Vyripharm Enterprises are jointly developing an automated laboratory testing platform. This solution will increase productivity and significantly advance the future of patient care.
Software and robotics
The new technology will enable quality control of raw materials to novel pharmaceutical compounds using a unique and comprehensive platform developed to allow certification of the tested samples against established standards. This fully automated robotic platform will be the first of its kind and will support the capture of data for use in research and development efforts within industry and health institutions.
Under the terms of the partnership, ABB will provide state-of-the-art automation software and robotics to demonstrate the operational function of the integrative platforms. ABB Life Sciences and Healthcare Solutions is the leader in the integration of automation across the Life Sciences supply chain.
Two beta sites, located in Texas and Colorado, are currently under construction and are expected to be operational in 2023, with other locations planned throughout the U.S. and internationally. Vyripharm will provide process definition, intellectual property (IP), equipment, software and associated funds. Its current diagnostic and therapeutic areas of emphasis are infectious diseases, neurological disorders, and cancer.
Two ABB divisions
In 2019, ABB opened its first dedicated global life sciences and healthcare research facility (ABB Life Sciences and Healthcare Solutions), in the Texas Medical Center (TMC) Innovation Institute. ABB Life Sciences and Healthcare Solutions hopes to bring advancement to the life sciences and healthcare industries, covering pharmaceutical and medical device production, and laboratory automation.
ABB Robotics collaborates with the medical community to co-develop innovative automation technologies that help hospitals and laboratories improve productivity and optimize processes. The collaborative effort between ABB and VEI, brings this concept to reality in the biopharma industry, advancing public health care and safety. Implementation of this process will support quality, capacity, and cost of operations improvements within the industry.
Optimize processes
“We are very happy to work together with Vyripharm to advance and automate its quality process,” said Jose Collados, Line Manager for ABB Life Sciences and Healthcare Robotic Solutions. “ABB’s automated solutions, when combined with Vyripharm’s process and software, will improve productivity and optimize processes.”
John W. Shadle, Managing Director of Vyripharm, said, “The rapid growth of the biopharma supply chain has produced a need for standardized testing to assure that the methods and instrumentation used in the testing process produce equivalent results across different laboratories. We have developed a process and protocol to achieve that goal.”
Text: SCCIJ with material of ABB/Vyripharm
